A quantitative enterohepatic circulation model: Development and evaluation with tesofensine and meloxicam

Clinical Pharmacokinetics

Volumn 48, Issue 8, 2009, Pages 529-542

  Lehr, Thorsten ^a,b   Staab, Alexander ^c   Tillmann, Christiane ^c   Trommeshauser, Dirk ^c   Schaefer, Hans Guenter ^c   Kloft, Charlotte ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; COLESTYRAMINE; MELOXICAM; PLACEBO; TESOFENSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ENTEROHEPATIC CIRCULATION; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE;

ADULT; BICYCLO COMPOUNDS, HETEROCYCLIC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENTEROHEPATIC CIRCULATION; EVALUATION STUDIES AS TOPIC; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; THIAZINES; THIAZOLES; YOUNG ADULT;

EID: 69249141803     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11313370-000000000-00000     Document Type: Article

References (34)

1. Roberts MS, Magnusson BM, Burczynski FJ, et al. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41: 751-90
2. Gabrielsson J, Weiner D. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. 3rd ed. Stockholm: Taylor & Francis, 2000
3. Mahmood I, Sahajwalla C. Interspecies scaling of biliary excreted drugs. J Pharm Sci 2002; 91: 1908-14
4. Mahmood I. Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci 2005; 94: 883-92
5. Steimer JL, Plusquellec Y, Guillaume A, et al. A. time-lag model for pharmacokinetics of drugs subject to enterohepatic circulation. J Pharm Sci 1982; 71:297-302
6. Hoglund P, Ohlin M. Effect modelling for drugs undergoing enterohepatic circulation. Eur J Drag Metab Pharmacokinet 1993; 18: 333-8
7. Khalil FA, Hanocq M., Dubois J. A. new method to estimate parameters of pharmacokinetics with enterohepatic circulation. Eur J Drag Metab Pharmacokinet 1993; 18: 131-9
8. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol 1999; 51:1143-8
9. Ezzet F, Krishna G, Wexler DB, et al. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23: 871-85
10. Wajima T, Yano Y, Oguma T. A pharmacokinetic model for analysis of drug disposition, profiles undergoing enterohepatic circulation. J Pharm. Pharmacol 2002; 54: 929-34
11. Wang YMC, Reuning RH, An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example. Pharm Res 1992; 9: 169-77
12. Huntjens DRH, Strougo A, Chain A, et al. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol 2008; 153: 1072-84
13. Jiao Z, Ding JJ, Shen J, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT.1A9. Br J Clin Pharmacol 2008; 65: 893-907
14. Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological, activity of tesofensine in vivo: a pharmacokineticpharmacodynamic modelling approach. Br J Pharmacol 2008; 153: 164-74
15. Thatte U. NS-2330 NeuroSearch. Curr Opin Investig Drugs 2001; 2: 1592-4
16. Bara-Jimenez W, Dimitrova T, Sherzai A, et al. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Mov Disord 2004; 19:1183-6
17. Lehr T, Staab A, Tillmann. C, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007; 64: 36-48
18. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new nonsteroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48: 269-72
19. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35: 13-6
20. Türck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 1997; 47: 253-8
21. Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam.: a cyclooxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet .1999; 36: 115-26
22. Gates BJ, Nguyen TT, Setter SM, et al. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother 2005; 6: 2117-40
23. Beal SL, Sheiner LB. NONMEM users guide: conditional estimation methods. San Francisco (CA): University of California, 1998
24. Akaike H. A new look at the statistical, model identification. IEEE Trans Automatic Control 1974; 19: 716-23
25. Jonsson EN, Karlsson MO. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64
26. Sheiner LB. Analysis of pharmacokinetic data using parametric models: III, hypothesis tests and confidence intervals. J Pharmacokinet Biopharm 1986; 14: 539-55
27. Montgomery DC, Peck EA, Vinters HV. Introduction to linear regression analysis. Chichester (NY): Wiley, 2001
28. Parke J, Holford NHG, Charles BG. A. procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed .1999; 59: 19-29
29. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95
30. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related, programming. Comput Methods Programs Biomed 2004; 75: 85-94
31. Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202
32. Shaffer EA. Control, of gall-bladder motor function. Aliment Pharmacol Ther 2000; 14: 2-8
33. Fisher RS, Stelzer F, Rock. E, et al. Abnormal gallbladder emptying in patients with gallstones. Digest Dis Sci 1982; 27: 1019-24
34. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41: 421-30